Neurology
Conference Coverage
ATTAIN: Peginterferon beta-1a remains efficacious for MS in long term
Key clinical point: Peginterferon beta-1a has sustained efficacy in treating relapsing-remitting multiple sclerosis for at least 6 years. Major...
Conference Coverage
Long-term use of opioids for musculoskeletal pain incurs major risks
Key clinical point: The use of opioids for musculoskeletal pain for more than 3 months is associated with significantly increased risk for many...
Conference Coverage
Doppler ultrasound headset performs well at spotting sports-related concussion
Key clinical point: Advanced transcranial Doppler analysis may improve identification of athletes with concussion at the point of care. Major...
News
Opioid reform legislation passes House committee
Conference Coverage
Scans show high prevalence of TBI among symptomatic retired NFL players
Key clinical point: MRI findings suggest that traumatic brain injury is prevalent among symptomatic retired NFL players. Major finding: Overall,...
Conference Coverage
Fewer new lesions, side effects differentiate fingolimod from dimethyl fumarate
Key clinical point: Multiple sclerosis patients discontinued treatment and relapsed earlier when treated with dimethyl fumarate (Tecfidera) than...
News
$30 million NIA consortium explores links between vascular health and Alzheimer’s disease
News
$30 million NIA Consortium Explores Links Between Vascular Health and Alzheimer Disease
Video
VIDEO: How to personalize pain management in era of opioids
As the prescription opioid crisis rages, how physicians evaluate, define, and treat chronic pain is evolving.
Conference Coverage
Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – A better amantadine option may be coming soon.
Conference Coverage
Small study: OTC antihistamine shows potential as a remyelinating agent in MS
Key clinical point: Clemastine led to a modest reduction in visual evoked potential delay in MS patients with chronic, stable optic neuropathy....